Home Contact Sitemap login Checkout

BioAlberta
  • Home
  • About
    • About
    • The BioAlberta Team
    • From The President
    • What We Do
    • Board of Directors
    • Committees
    • Industry Partners
    • Hall Of Fame
  • Boosting Biotech
  • Industry Facts
    • Industry Facts
    • Medical Technology & Devices
    • Health Biotechnology & Pharmaceuticals
    • Agricultural Biotechnology
    • Industrial Biotechnology
    • Functional Foods & Natural Health Products
    • Environmental Biotechnology
    • Industry Terms
  • Events
    • Events
    • Annual Events & Activities
    • Archived Events
      • Archived Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
      • 2017 Events
      • 2016 Events
      • 2015 Events
      • 2014 Events
  • News
    • News
    • Archived News
      • Archived News
      • 2020 News
      • 2019 News
      • 2018 News
      • 2017 news
      • 2016 News
      • 2015 News
      • 2014 News
  • Member Area
    • Member Area
    • Member Marketplace
    • Join Now
    • Member Benefits
      • Member Benefits
      • How To Access Member Benefits
    • Current Members and Life Sciences Industry
    • Current Members by Category
    • Profiled Company
      • Profiled Company
      • Previously Profiled Companies
  • Resources
    • Resources
    • Other Resources
  • Contact
Home Print This Page

EXCITON TECHNOLOGIES INC. MAKES TURN TO PROFITABILITY

 

 Edmonton, Alberta, Canada - March 8, 2016 - Exciton Technologies Inc., creator of the patented infection-fighting Silver Oxysalts technology, has made a pivotal turn to profitability through expansion of its license agreement with Crawford Healthcare Ltd., the UK’s fastest growing wound care company. Exciton has been working with Crawford since 2013 but, following what Crawford calls “a dramatic market response to the use of this patented technology in both the US and the UK,” the companies have now expanded to an exclusive global arrangement for a broader range of products. Commenting on the deal, Crawford’s Healthcare CEO, Richard Anderson said, “We now have an unrivalled antimicrobial platform to tackle the issue of secondary infections faced by clinicians the world over.”

 

Read full press release details.

Contact Us
Suite 202
10055 - 106 Street NW
Edmonton, Alberta T5J 2Y2
Canada
Ph:  780.425.3804
Fx:  780.409.9263
admin@BioAlberta.com
Quick Links
Home
About
Industry Facts
News
Events
Member Area
Publications
Contact
Return Policy
Privacy
Terms of Use
Connect
BioAlberta: Twitter linkBioAlberta: linkedin linkBioAlberta: YouTube linkBioAlberta: facebook link